Format

Send to

Choose Destination
Curr Opin Pharmacol. 2018 Dec;43:20-26. doi: 10.1016/j.coph.2018.07.007. Epub 2018 Jul 30.

Pluripotent stem cell replacement approaches to treat type 1 diabetes.

Author information

1
Diabetes Research Institute - IRCCS San Raffaele Scientific Institute, Italy.
2
Diabetes Research Institute - IRCCS San Raffaele Scientific Institute, Italy; Vita-Salute San Raffaele University, Italy.
3
Diabetes Research Institute - IRCCS San Raffaele Scientific Institute, Italy. Electronic address: sordi.valeria@hsr.it.

Abstract

Stem cells represent a potential candidate for β cell replacement in type 1 diabetes. Pluripotent stem cells are able to differentiate in vitro into functional insulin producing cells, that can restore normoglycemia in diabetic mice. Clinical trials with embryonic stem cell-derived pancreatic progenitors are ongoing. Besides, induced pluripotent stem cells offer the chance of personalized cell therapy. So far, transition to the clinic still needs to face critical issues, such as immunogenicity and safety of stem cell derived β cells. To this purpose, new strategies for immunoprotection, including micro and macro-encapsulation, but also gene editing approaches, are being explored.

PMID:
30071348
DOI:
10.1016/j.coph.2018.07.007

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center